Australia markets close in 2 hours 15 minutes

CytomX Therapeutics, Inc. (CTMX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.11+0.04 (+0.79%)
At close: 4:00PM EDT
5.14 +0.03 (+0.59%)
After hours: 05:17PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close5.07
Open5.05
Bid5.08 x 1800
Ask5.14 x 900
Day's range5.05 - 5.16
52-week range4.28 - 10.05
Volume209,566
Avg. volume555,120
Market cap332.952M
Beta (5Y monthly)0.71
PE ratio (TTM)N/A
EPS (TTM)-1.17
Earnings date03 Nov 2021 - 08 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.14
  • GlobeNewswire

    CytomX Therapeutics Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced that on October 15, 2021, the Company granted six new employees options to purchase a total of 177,000 shares of the Company’s common stock at an exercise price per share equal to $5.14, which w

  • GlobeNewswire

    CytomX Therapeutics Appoints Dr. Alan Ashworth to Board of Directors

    SOUTH SAN FRANCISCO, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced the appointment of Alan Ashworth, Ph.D., FRS, a world-renowned expert in cancer research and a global leader in cancer therapy development, to the company’s board of directors. “It is a privilege

  • GlobeNewswire

    CytomX Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in a virtual fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference, being